Resources for you and your patients.

Want to know more about EYLEA? The following resources are available to download or email so that you can learn more about EYLEA or provide information to patients who need it.


Search Resources
clear

Indication


Resource Type


Category



No Results Found

Try searching again with a different keyword and/or filter selection.

{{vm.paginationDirection}} {{vm.showInfo}}

Email Share

To share {{vm.selectedItemText}} please fill out the information below.

To share {{vm.selectedItemText}} please fill out the information below.

Please enter a valid recipient email address Please enter a valid recipient email address
Please enter your name
Please enter a valid email address Please enter a valid email address

In My Eyes by Regeneron logo.

Experience what certain retinal diseases can be like in virtual reality

Retinal disease virtual and augmented reality app
  • Available on the App Store.
  • Android app on Google play.

A powerful teaching tool to use with your patients and caregivers, this unique app lets the user experience retinal disease symptoms firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

Retinal disease virtual and augmented reality app.
  • Available on the App Store.
  • Android app on Google play.
Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
Product support for Eylea.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
EYLEA news, events, and more.
News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.